Mechanistically, the present study demonstrates that combination treatment with alisertib—an Aurora kinase A inhibitor—overcomes the aforementioned lack of treatment response in adult MLLr leukemia, possibly by modulating these feedback mechanisms. This evidence concerns the gene AURKA and leukemia.